Nuvalent Net Income Applicable To Common Shares Over Time
| NUVL Stock | USD 96.68 0.08 0.08% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Nuvalent Performance and Nuvalent Correlation. Nuvalent |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nuvalent. If investors know Nuvalent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nuvalent listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.49) | Return On Assets (0.19) | Return On Equity (0.30) |
The market value of Nuvalent is measured differently than its book value, which is the value of Nuvalent that is recorded on the company's balance sheet. Investors also form their own opinion of Nuvalent's value that differs from its market value or its book value, called intrinsic value, which is Nuvalent's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nuvalent's market value can be influenced by many factors that don't directly affect Nuvalent's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nuvalent's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nuvalent is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nuvalent's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Applicable To Common Shares Analysis
Compare Nuvalent and related stocks such as Dice Molecules Holdings, Arcellx, and Vaxcyte Net Income Applicable To Common Shares Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ACLX | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (8.3 M) | (18 M) | (32.1 M) | (65 M) | (188.7 M) | (169.8 M) | (161.3 M) |
| PCVX | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (17.2 M) | (29.5 M) | (50.3 M) | (89.2 M) | (100.1 M) | (223.5 M) | (201.1 M) | (191.1 M) |
| VRDN | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (17.3 M) | (26.5 M) | (32.7 M) | (41.9 M) | (110.7 M) | (79.4 M) | (129.9 M) | (116.9 M) | (111 M) |
| VTYX | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (4.3 M) | (28.2 M) | (85.3 M) | (108.4 M) | (97.6 M) | (92.7 M) |
| CGEM | (704.7 K) | (704.7 K) | (704.7 K) | (704.7 K) | (130.5 K) | (109.5 K) | (316.7 K) | (14.2 M) | (14.2 M) | (20.7 M) | (51.8 M) | (65.6 M) | 111.2 M | 127.9 M | 134.3 M |
| KNSA | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (24 M) | (64.9 M) | (103.2 M) | (161.9 M) | (161.4 M) | (157.9 M) | 183.4 M | 210.9 M | 221.4 M |
| REPL | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (7.7 M) | (19.7 M) | (30.8 M) | (52.6 M) | (80.9 M) | (118 M) | (118 M) | (106.2 M) | (100.9 M) |
| ASND | 4.1 M | 4.1 M | 4.1 M | 4.1 M | (11.7 M) | (32.9 M) | (68.5 M) | (123.9 M) | (130.1 M) | (218 M) | (419 M) | (383.6 M) | (583.2 M) | (524.9 M) | (498.6 M) |
| UTHR | 15.4 M | 217.9 M | 304.4 M | 174.6 M | 340.1 M | 651.6 M | 713.7 M | 417.9 M | 589.2 M | (104.5 M) | 514.8 M | 475.8 M | 727.3 M | 836.4 M | 878.2 M |
| TVTX | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (59.7 M) | (102.7 M) | (146.4 M) | (169.4 M) | (180.1 M) | (278.5 M) | (250.6 M) | (238.1 M) |
| GPCR | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (16 M) | (43.8 M) | (43.8 M) | (39.4 M) | (41.4 M) |
Nuvalent and related stocks such as Dice Molecules Holdings, Arcellx, and Vaxcyte Net Income Applicable To Common Shares description
The net income that remains after preferred dividends have been deducted, available to common shareholders.My Equities
My Current Equities and Potential Positions
| Nuvalent | NUVL |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 96.68
Check out Nuvalent Performance and Nuvalent Correlation. For more information on how to buy Nuvalent Stock please use our How to buy in Nuvalent Stock guide.You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Nuvalent technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.